Regeneron expects continuing demand for its COVID-19 therapy
Reuters
Published May 06, 2021 06:39AM ET
Updated May 06, 2021 11:22AM ET
By Mrinalika Roy and Manojna Maddipatla
(Reuters) -Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday and said it expects demand for its COVID-19 antibody therapy to hold up even as vaccination efforts across the United States intensify.
The comments were in contrast to those by rival Eli Lilly (NYSE:LLY) and Co, which last month trimmed its 2021 profit target as demand for Lilly's COVID-19 antibody therapies took a hit due to vaccinations.
Lilly's antibody therapies and Regeneron (NASDAQ:REGN)'s REGEN-COV have been authorized in the U.S. for treating non-hospitalized COVID-19 patients, and the companies have signed supply agreements with the U.S. government worth millions.
Demand for these therapies, however, has been lackluster due to the complexities involved in their administration.
Still, Regeneron said its therapy brought in U.S. sales of $262 million in the first quarter, ahead of estimates of $255 million, according to brokerage Piper Sandler.
"Despite high rates of vaccination, it's estimated that tens of millions will remain unvaccinated in the U.S. alone," Regeneron Chief Executive Officer Leonard Schleifer said.
Regeneron is also pursuing U.S. authorization of a lower dose of its antibody cocktail and for its use as a preventive medicine. It has reported positive data for both from clinical studies.
The drugmaker said it expects a decision from the U.S. health regulator on the authorization of the lower 1.2 g dose over the next several weeks.
Given the success of the lower dose based on trial data, REGEN-COV's sales will remain strong even during the second half of 2021, after Regeneron's supply contract with the United States is filled in the second quarter, Cowen analyst Yaron Werber said.
Regeneron's shares rose 2% to $490.90 after it beat estimates for first-quarter profit, helped in part by a recovery in demand for its physician-administered eye drug Eylea.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.